South Africa’s antitrust regulator wants Roche penalized for ‘excessive’ cancer drug pricing
Published on: Tuesday 08 February 2022
South Africa’s antitrust regulator has recommended that Roche (RHHBY) should be penalized for allegedly “excessive” pricing of its Herceptin breast cancer treatment, arguing it violates basic human ...